000182309 001__ 182309
000182309 005__ 20240229145715.0
000182309 0247_ $$2doi$$a10.3390/cancers14205044
000182309 0247_ $$2pmid$$apmid:36291828
000182309 0247_ $$2altmetric$$aaltmetric:137749269
000182309 037__ $$aDKFZ-2022-02566
000182309 041__ $$aEnglish
000182309 082__ $$a610
000182309 1001_ $$00000-0001-7488-6885$$aFincke, Victoria E$$b0
000182309 245__ $$aRenal Medullary Carcinomas Harbor a Distinct Methylation Phenotype and Display Aberrant Methylation of Genes Related to Early Nephrogenesis.
000182309 260__ $$aBasel$$bMDPI$$c2022
000182309 3367_ $$2DRIVER$$aarticle
000182309 3367_ $$2DataCite$$aOutput Types/Journal article
000182309 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667214658_12892
000182309 3367_ $$2BibTeX$$aARTICLE
000182309 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182309 3367_ $$00$$2EndNote$$aJournal Article
000182309 500__ $$a#LA:B062#
000182309 520__ $$aRenal medullary carcinomas (RMC) are rare aggressive tumors of the kidneys, characterized by a loss of SMARCB1. Characteristically, these tumors arise in patients with sickle cell trait or other hemoglobinopathies. Recent characterization efforts have unraveled oncogenic pathways that drive tumorigenesis. Among these, gene sets that characterize replicative stress and the innate immune response are upregulated in RMCs. Despite comprehensive genetic and transcriptomic characterizations, commonalities or differences to other SMARCB1 deficient entities so far have not been investigated. We analyzed the methylome of seven primary RMC and compared it to other SMARCB1 deficient entities such as rhabdoid tumors (RT) and epithelioid sarcomas using 850 K methylation arrays. Moreover, we evaluated the differential gene expression of RMC using RNA-sequencing in comparison to other rhabdoid tumors. In accordance with previous gene expression data, we found that RMCs separate from other SMARCB1 deficient entities, pointing to a potentially different cell of origin and a role of additional genetic aberrations that may drive tumorigenesis and thus alter the methylome when compared to rhabdoid tumors. In a focused analysis of genes that are important for nephrogenesis, we particularly detected genes that govern early nephrogenesis such as FOXI1 to be hypomethylated and expressed at high levels in RMC. Overall, our analyses underscore the fact that RMCs represent a separate entity with limited similarities to rhabdoid tumors, warranting specific treatment tailored to the aggressiveness of the disease.
000182309 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000182309 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182309 650_7 $$2Other$$aDNA methylation
000182309 650_7 $$2Other$$aSMARCB1 loss
000182309 650_7 $$2Other$$arenal medullary carcinoma
000182309 7001_ $$aKrulik, Mateja E$$b1
000182309 7001_ $$0P:(DE-He78)ee036c22158d4b18f5228616af640355$$aJoshi, Piyush$$b2$$udkfz
000182309 7001_ $$aFrühwald, Michael C$$b3
000182309 7001_ $$aChen, Ying-Bei$$b4
000182309 7001_ $$0P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aJohann, Pascal$$b5$$eLast author$$udkfz
000182309 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14205044$$gVol. 14, no. 20, p. 5044 -$$n20$$p5044$$tCancers$$v14$$x2072-6694$$y2022
000182309 909CO $$ooai:inrepo02.dkfz.de:182309$$pVDB
000182309 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ee036c22158d4b18f5228616af640355$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182309 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3fdc3623477264cb5d0e14f256dbfbb8$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182309 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000182309 9141_ $$y2022
000182309 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000182309 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000182309 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000182309 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000182309 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000182309 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000182309 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000182309 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000182309 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000182309 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000182309 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000182309 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000182309 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000182309 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000182309 980__ $$ajournal
000182309 980__ $$aVDB
000182309 980__ $$aI:(DE-He78)B062-20160331
000182309 980__ $$aI:(DE-He78)HD01-20160331
000182309 980__ $$aUNRESTRICTED